Pharmaron

Beijing, China Founded: 2003 • Age: 23 yrs
Drug discovery and development services for small molecules are provided.
Annual revenue - Latest available
Total funding $320.0M 5 rounds
Employees 476 Tracked headcount
Investors 6 Known backers
Products - Services tracked
Competitors 9 Brand Intelligence

About Pharmaron

Pharmaron is a company based in Beijing (China) founded in 2003 by Larry Lou, Bei Zheng, and Boliang Lou. Pharmaron has raised $320 million across 5 funding rounds from investors including HHS, CITIC Capital and Legend Capital. The company has 476 employees as of December 31, 2021. Pharmaron has completed 6 acquisitions, including Absorption, Aesica and Allergan. Pharmaron operates in a competitive market with competitors including Lonza, Pfizer, Boehringer Ingelheim, LabConnect and Ainos, among others.

  • Headquarter Beijing, China
  • Employees 476 as on 31 Dec, 2021
  • Founders Larry Lou, Bei Zheng, Boliang Lou
  • Stage Public
  • Sectors
    Healthcare
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
Operational Areas
Healthcare → Healthcare Services & Infrastructure Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Total Equity Funding
    $320 M (USD)

    in 5 rounds

  • Latest Funding Round
    $280 M (USD), Private Equity Round

    Dec 14, 2015

  • Investors
    HHS

    & 5 more

  • Employee Count
    476

    as on Dec 31, 2021

  • Investments & Acquisitions
    Absorption

    & 5 more

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

People of Pharmaron

Headcount 1000-5000
Employee Profiles 287
Employee Profiles
People
Chad McRoberts
Director Of Quality Assurance
People
Jessica Reeb
Quality Control Manager
People
Dylan Jones
Senior Validation Manager
People
Jufeng Wang
SVP, Safety Assessment

Unlock access to complete

Funding Insights of Pharmaron

Pharmaron has successfully raised a total of $320M across 5 strategic funding rounds. The most recent funding activity was a Private Equity Round of $280 million completed in December 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investors in Pharmaron

Pharmaron has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS, CITIC Capital and Legend Capital.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Venture Capital firm focused on multiple sectors
Locked Locked Locked
Tech-focused seed, early, and mid-stage VC investments are made globally.
Locked Locked Locked
PE firm investing in the US
Locked Locked Locked
Premium access

Investor details for Pharmaron

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Pharmaron

Pharmaron has strategically engaged in corporate development activities, having acquired 6 companies. Notable acquisitions include Absorption, Aesica and Allergan.

Investments
Premium access

Investment portfolio details for Pharmaron

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Acquisitions
Company Name Description Domain Location Founded Year Amount
Full service, early phase CRO specializing in complex trials
Locked Locked 2006 Locked
Contract development and manufacturing organisation (CDMO) for APIs and finished dose forms
Locked Locked 2004 Locked
Accelerator Mass Spectrometry is utilized by Xceleron for pharmaceutical analysis.
Locked Locked 1997 Locked
Premium access

Complete acquisition details for Pharmaron

Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.

  • Transaction dates
  • Acquired stakes
  • Disclosed values
  • Domains and locations

Verified entity values are shown only after access is granted.

Financial Statements - Pharmaron

Premium access

Detailed financials for Pharmaron

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Pharmaron Comparisons

Pharmaron Primary company
Description
Drug discovery and development services for small molecules ...
Location
Beijing, China
Founded Year
2003
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
476
As of 2021
Premium access

Peer comparison for Pharmaron

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Pharmaron

Pharmaron operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Lonza, Pfizer, Boehringer Ingelheim, LabConnect and Ainos, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
CDMO services for pharma, biotech, and specialty ingredients are provided.
Locked Locked Locked
Pharmaceutical products for treating multiple diseases are provided.
Locked Locked Locked
Generic drugs and clinical research services are provided globally.
Locked Locked Locked
Laboratory testing, clinical trial research, and biopharma services are provided.
Locked Locked Locked
Novel point-of-care testing and low-dose interferon therapeutics are developed.
Premium access

Detailed competitors of Pharmaron

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Pharmaron

Premium access

Complete news archive for Pharmaron

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Pharmaron

Pharmaron was founded in 2003 and raised its 1st funding round 5 years after it was founded.

Pharmaron is headquartered in Beijing, China.

Boliang Lou is the current CEO of Pharmaron. They have also founded this company.

Pharmaron is a funded company, having raised a total of $320M across 5 funding rounds to date.

As of Dec 31, 2021, the latest employee count at Pharmaron is 476.

Founded in 2003 and headquartered in Beijing, China, Pharmaron operates in the pharmaceutical sector, focusing on research and development services for small molecules, nucleosides, nucleotides, peptides, lipids, and carbohydrates. Disciplines covered include chemistry, biology, DMPK, pharmacology, toxicology, and formulation development. Expertise encompasses organic synthesis, medicinal chemistry, biologics engineering, protein expression, and purification. Acquisitions of Xceleron and SNBL CPC have expanded the service portfolio.

Pharmaron's top competitors include Pfizer, Lonza and Boehringer Ingelheim.

Pharmaron has made 6 acquisitions, including Absorption, Aesica, and Allergan.

Pharmaron has 6 investors. Key investors include HHS, CITIC Capital, Legend Capital, DCM, and Aisling Capital.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available